Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation

do they matter?

Tania Jain, Katie L. Kunze, Banveet K. Khetarpal, Margaret R. McCallen, Jeffrey A. Betcher, Henry T. Ofori, Nandita D Khera, James L Slack, Jose F. Leis, Lisa Sproat, Pierre Noel, Jeanne Palmer

Research output: Contribution to journalArticle

Abstract

Therapeutic dose monitoring is widely adopted for determination of busulfan (Bu) dose for use as a conditioning regimen. However, while dose adjustments are being incorporated, transient fluctuations of Bu levels may occur. We aim to understand if these fluctuations affect clinical outcomes of these patients. We compared outcomes in patients in whom the absolute dose changes and fluctuation of AUC were ≥ median% versus < median%. Rates of sinusoidal obstructive syndrome, grades 2–4/grades 3–4 acute and chronic graft versus host disease were not different between the two cohorts. The Kaplan–Meier curves for overall survival showed no significant differences. Six patients required >50% dose adjustment and four had a fluctuation in AUC of >50%. One of these patients died of sinusoidal obstruction syndrome and two died of infections. In our study, the transient fluctuations in Bu levels did not affect clinical outcomes; hence obviating the need for test dose strategy.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Busulfan
Stem Cell Transplantation
Area Under Curve
Hepatic Veno-Occlusive Disease
Therapeutics
Infection

Keywords

  • Busulfan
  • conditioning regimen
  • therapeutic dose monitoring

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation : do they matter? / Jain, Tania; Kunze, Katie L.; Khetarpal, Banveet K.; McCallen, Margaret R.; Betcher, Jeffrey A.; Ofori, Henry T.; Khera, Nandita D; Slack, James L; Leis, Jose F.; Sproat, Lisa; Noel, Pierre; Palmer, Jeanne.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

Jain, Tania ; Kunze, Katie L. ; Khetarpal, Banveet K. ; McCallen, Margaret R. ; Betcher, Jeffrey A. ; Ofori, Henry T. ; Khera, Nandita D ; Slack, James L ; Leis, Jose F. ; Sproat, Lisa ; Noel, Pierre ; Palmer, Jeanne. / Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation : do they matter?. In: Leukemia and Lymphoma. 2019.
@article{3fd818b81d044e2d9cecd8387aff6144,
title = "Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?",
abstract = "Therapeutic dose monitoring is widely adopted for determination of busulfan (Bu) dose for use as a conditioning regimen. However, while dose adjustments are being incorporated, transient fluctuations of Bu levels may occur. We aim to understand if these fluctuations affect clinical outcomes of these patients. We compared outcomes in patients in whom the absolute dose changes and fluctuation of AUC were ≥ median{\%} versus < median{\%}. Rates of sinusoidal obstructive syndrome, grades 2–4/grades 3–4 acute and chronic graft versus host disease were not different between the two cohorts. The Kaplan–Meier curves for overall survival showed no significant differences. Six patients required >50{\%} dose adjustment and four had a fluctuation in AUC of >50{\%}. One of these patients died of sinusoidal obstruction syndrome and two died of infections. In our study, the transient fluctuations in Bu levels did not affect clinical outcomes; hence obviating the need for test dose strategy.",
keywords = "Busulfan, conditioning regimen, therapeutic dose monitoring",
author = "Tania Jain and Kunze, {Katie L.} and Khetarpal, {Banveet K.} and McCallen, {Margaret R.} and Betcher, {Jeffrey A.} and Ofori, {Henry T.} and Khera, {Nandita D} and Slack, {James L} and Leis, {Jose F.} and Lisa Sproat and Pierre Noel and Jeanne Palmer",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1562183",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation

T2 - do they matter?

AU - Jain, Tania

AU - Kunze, Katie L.

AU - Khetarpal, Banveet K.

AU - McCallen, Margaret R.

AU - Betcher, Jeffrey A.

AU - Ofori, Henry T.

AU - Khera, Nandita D

AU - Slack, James L

AU - Leis, Jose F.

AU - Sproat, Lisa

AU - Noel, Pierre

AU - Palmer, Jeanne

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Therapeutic dose monitoring is widely adopted for determination of busulfan (Bu) dose for use as a conditioning regimen. However, while dose adjustments are being incorporated, transient fluctuations of Bu levels may occur. We aim to understand if these fluctuations affect clinical outcomes of these patients. We compared outcomes in patients in whom the absolute dose changes and fluctuation of AUC were ≥ median% versus < median%. Rates of sinusoidal obstructive syndrome, grades 2–4/grades 3–4 acute and chronic graft versus host disease were not different between the two cohorts. The Kaplan–Meier curves for overall survival showed no significant differences. Six patients required >50% dose adjustment and four had a fluctuation in AUC of >50%. One of these patients died of sinusoidal obstruction syndrome and two died of infections. In our study, the transient fluctuations in Bu levels did not affect clinical outcomes; hence obviating the need for test dose strategy.

AB - Therapeutic dose monitoring is widely adopted for determination of busulfan (Bu) dose for use as a conditioning regimen. However, while dose adjustments are being incorporated, transient fluctuations of Bu levels may occur. We aim to understand if these fluctuations affect clinical outcomes of these patients. We compared outcomes in patients in whom the absolute dose changes and fluctuation of AUC were ≥ median% versus < median%. Rates of sinusoidal obstructive syndrome, grades 2–4/grades 3–4 acute and chronic graft versus host disease were not different between the two cohorts. The Kaplan–Meier curves for overall survival showed no significant differences. Six patients required >50% dose adjustment and four had a fluctuation in AUC of >50%. One of these patients died of sinusoidal obstruction syndrome and two died of infections. In our study, the transient fluctuations in Bu levels did not affect clinical outcomes; hence obviating the need for test dose strategy.

KW - Busulfan

KW - conditioning regimen

KW - therapeutic dose monitoring

UR - http://www.scopus.com/inward/record.url?scp=85059895222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059895222&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1562183

DO - 10.1080/10428194.2018.1562183

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -